PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33405241-0	2021	Angiotensin II receptor blockers valsartan and losartan improve survival rate clinically and suppress tumor growth via apoptosis related to PI3K/AKT signaling in nasopharyngeal carcinoma.	Losartan	47-55	AKT serine/threonine kinase 1	Homo sapiens	145-148	
32186097-9	2019	Real-time PCR and western blotting analyses showed that the expression levels of PI3K, Akt, and mTOR in SHRs were significantly up-regulated by EA and Losartan (P < 0.01), while the expression levels of PTEN and ANP were down-regulated (P < 0.01).	Losartan	151-159	AKT serine/threonine kinase 1	Homo sapiens	87-90	
32969473-7	2020	The levels of phosphorylated phosphatidylinositol 3-kinase (p-PI3K) and phosphorylated protein kinase B (p-Akt) were increased by Ang II and then reduced by losartan in SNK-6 cells.	Losartan	157-165	AKT serine/threonine kinase 1	Homo sapiens	107-110	
28518223-10	2018	We also found that Losartan markedly increased endothelial NO synthase (eNOS) phosphorylation at Ser(633,1177) and dephosphorylation at Thr(495), which involved AKT and ERK.	Losartan	19-27	AKT serine/threonine kinase 1	Homo sapiens	161-164	
28008588-2	2017	In this study, we demonstrate that losartan administration increased phosphorylation of Akt and its downstream Akt substrate of 160 kDa (AS160), enhanced plasma membrane translocation of glucose transporter type 4 (GLUT4), and increased glucose uptake, along with increased Src phosphorylation as well as reduced expression of docking protein 1(DOK1) in palmitate-treated 3T3-L1 adipocytes.	Losartan	35-43	AKT serine/threonine kinase 1	Homo sapiens	88-91	
34604421-6	2021	By adding receptors antagonists (losartan, AT1R antagonist and PD 123319, AT2R antagonist) and/or signaling modulators for AMPK, Akt/PI3K, p38 and PKC we showed the protective effect was enhanced with losartan and abolished with PD 123319.	Losartan	201-209	AKT serine/threonine kinase 1	Homo sapiens	129-132	
28008588-5	2017	Our results suggest that anti-insulin resistance ability of losartan is mediated by Src/DOK1/Akt pathway.	Losartan	60-68	AKT serine/threonine kinase 1	Homo sapiens	93-96	
10692557-7	2000	For candesartan this effect was concentration-dependent, yielding a pK(B) value for losartan of 7.7, which is similar to the pK(B) from previously obtained AT concentration-response curves.	Losartan	84-92	AKT serine/threonine kinase 1	Homo sapiens	68-72